Cipla Update by Epic Research

Cipla has reportedly entered into agreement with Hetero to launch Darbepoetin Alfa in India. Darbepoetin Alfa is a synthetic form of erythropoietin, clinically proven to stimulate erythropoiesis (increased hemoglobin levels) for patients with anemia due to chronic kidney disease.



Real Time News & Trading Trends Keep Liking Epic Research Private Limited



Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+



For more information ✆ – 0731-6642300 or Visit http://ift.tt/1k8NnLH

Posted in: Indian Market Tips